What You Should Know

• Moderna has selected Salesforce’s Agentforce Life Sciences to serve as its unified, global platform for commercial operations and customer engagement.
• The platform will consolidate data from SAP, ecommerce, and regional systems to create a single “Customer 360” source of truth for all healthcare provider (HCP) interactions.
• Field teams will utilize AI-powered agents to automate cycle planning, deliver “next best action” recommendations, and streamline real-time call reporting.
• The system is fueled by IQVIA OneKey, providing Moderna with secure, real-time reference data and master data management (MDM) capabilities.
• The architecture is designed for unification, connecting commercial, medical, patient services, and contact center operations into one open ecosystem to prevent vendor lock-in.

Moderna, a biotechnology leader built on the foundation of rapid innovation, has moved to modernize its global commercial infrastructure by selecting Salesforce’s Agentforce Life Sciences. This strategic collaboration is designed to eliminate the data silos that frequently hinder global commercial teams. By shifting to a single, connected platform, Moderna aims to deliver a unified customer experience that is powered by a 360-degree understanding of healthcare providers (HCPs) across multiple regional markets.

The initiative represents a fundamental shift from fragmented regional systems to an integration-first architecture. By bringing together commercial, medical, and patient service operations, Moderna is positioning itself to scale its marketing and field efforts without the traditional friction of disparate software tools. This unified approach ensures that every interaction—whether from a sales representative in the field or a contact center agent—is grounded in the same trusted data.

AI-Powered Commercial Excellence and Real-Time Insights

At the heart of this transformation is the deployment of Agentforce, Salesforce’s advanced AI infrastructure. Moderna’s field teams will leverage these AI agents to move beyond manual reporting and planning. The platform will automatically generate intelligent recommendations and next best actions, allowing commercial users to engage HCPs with higher precision. Automation will also play a critical role in cycle planning and call reporting, freeing up significant time for representatives to focus on meaningful clinical discussions.

To ensure the accuracy of these AI-driven insights, the platform integrates IQVIA OneKey. This provides Moderna with access to one of the world’s most trusted sources of HCP reference data. By combining this real-time external data with internal information from SAP and ecommerce portals, the company can maintain a secure and private master data management layer. This “trusted data” foundation is what allows the AI agents to provide reliable, compliant recommendations in a highly regulated industry.

Global Omni-Channel Marketing and Scalable Growth

As Moderna continues to expand its global footprint, the ability to execute unified, cross-channel marketing campaigns is essential. The new platform enables the company to deliver personalized, data-driven engagement across both commercial and customer service channels. This ensures that the message received by an HCP is consistent, regardless of the channel through which they interact with the company.

Joe Ferraro, General Manager of Agentforce Life Sciences, noted that this collaboration reflects Moderna’s commitment to building a modern, AI-powered commercial organization. By leveraging an open ecosystem, Moderna can scale rapidly while building upon its existing investments. The result is a more agile organization capable of adapting to market shifts and regulatory changes with a level of decision-speed that was previously unattainable under a multi-vendor, siloed model.

Why This Matters

For the broader market, the integration of IQVIA OneKey directly into the Salesforce AI workflow is a significant technical upgrade. It moves the industry closer to a true “Zero-Trust” data model where compliance and accuracy are automated rather than checked. 

What You Should Know

• KLAS has released its 2026 Points of Light report, honoring 24 strategic partnerships that successfully improved data sharing, operational efficiency, and financial performance.
• Award recipients were validated through in-depth interviews conducted between September 2025 and February 2026.
• The report focuses on lowering costs and enhancing experiences for patients, providers, and payers through strong alignment and interoperability.
• Awarded partnerships demonstrated measurable outcomes in addressing critical healthcare pain points, moving beyond theory into validated case studies.
• The K2 Collaborative—a joint initiative between KLAS and several industry leaders—celebrates these “points of light” as blueprints for industry-wide replication.

The divide between payers and providers has historically been one of the most significant obstacles to healthcare innovation. However, the newly released KLAS Points of Light 2026 report suggests a fundamental shift toward collaborative problem-solving. By highlighting 24 successful partnerships among healthcare organizations and HIT vendors, the report provides a roadmap for how interoperability can be used to move past administrative friction and toward shared clinical and financial goals.

The awards are specifically designed to recognize “points of light”—instances where traditional adversaries have come together to streamline administrative processes and lower overall care costs. The methodology for these awards is rigorous, requiring KLAS to conduct in-depth interviews with all stakeholders to validate outcomes. This process ensures that the celebrated results are not just anecdotal but represent a reliable standard of excellence that other organizations can follow.

Proven Strategies for Reducing Administrative Friction

A central theme of the KLAS Points of Light 2026 report is the use of technology as a bridge, rather than a barrier. The awarded partnerships demonstrate that when HIT vendors act as neutral orchestrators, it becomes possible to align payer and provider workflows more effectively. These “best practices” identified in the report focus on three primary pillars:

1. Interoperability: Moving beyond simple data exchange to meaningful, real-time clinical data access that supports both payment integrity and care coordination.
2. Alignment: Creating shared incentives that encourage both sides to focus on the patient experience rather than defensive administration.
3. Measurable Impact: Establishing a shared baseline of truth that allows for the objective measurement of cost reductions and quality improvements.

The report’s executive insights reveal that the most successful organizations confronted shared challenges—such as prior authorization delays and clinical data gaps—by building end-to-end workflows that serve the interests of all three parties: the payer, the provider, and most importantly, the patient.

The Role of the K2 Collaborative in Industry Change

The Points of Light awards are a core component of the K2 Collaborative, an industry-wide effort to accelerate the adoption of interoperability. By showcasing validated case studies, the collaborative aims to provide a “peer-to-peer” learning environment. The 2026 report serves as an executive playbook, offering high-level overviews of the lessons learned by those who have successfully navigated the complexities of large-scale payer–provider integrations.

According to the report’s summary, the ultimate value of these partnerships is their ability to deliver “harmony” in a system that has long been out of tune. By celebrating these 24 “points of light,” KLAS is signaling that the technology to solve healthcare’s administrative crisis already exists; the missing ingredient has been the strategic willpower to collaborate across organizational boundaries.

Why This Matters

The report serves as a benchmarking tool that moves the conversation from “what could happen” with AI and APIs to “what did happen” in 24 diverse, real-world clinical settings. The key takeaway for 2026 is clear: the most profitable organizations will be those that stop fighting for data and start collaborating for outcomes.

What You Should Know

• UChicago Medicine has signed an enterprise agreement to deploy Artisight’s Smart Hospital Platform, implementing more than 1,800 devices across its clinical enterprise.
• The rollout covers diverse care settings, including patient rooms, operating rooms, PACUs, and a new 575,000-square-foot freestanding cancer facility opening in April 2027.
• The platform utilizes computer vision, voice recognition, and RTLS (Real-Time Location Services) to automate documentation and support Virtual Nursing and Virtual Sitting.
• Previous implementations of this technology have delivered significant clinical outcomes, including a 78 percent reduction in fall rates and a 4x increase in on-time discharges.
• The system operates on a shared sensor fabric, designed to eliminate fragmented point solutions and reduce administrative burden by over 30 minutes per nurse per shift.

The infrastructure of modern academic medicine is increasingly defined by the ability to unify data across complex, high-acuity environments. UChicago Medicine, a premier national health system, has moved to consolidate its digital clinical operations by entering into an enterprise agreement with Artisight. The implementation will see Artisight’s Smart Hospital Platform integrated into over 1,800 locations, providing a continuous intelligence layer that spans from standard patient rooms to high-complexity surgical suites.

This partnership addresses a foundational challenge in healthcare IT: the proliferation of “point solutions” that create data silos and increase the cognitive load on clinical staff. By utilizing a single platform for Virtual Nursing, Virtual Sitting, and workflow automation, UChicago Medicine is building a foundation that allows every clinical team to work from a shared infrastructure. This move is particularly critical as the system prepares to open its new, massive freestanding cancer care facility in 2027.

Automating the “In-Between” of Care Delivery

Artisight’s platform leverages advanced computer vision and voice-activated sensors—powered by NVIDIA GPUs—to bring intelligent awareness to the bedside. In the Operating Room (OR) and Post-Anesthesia Care Unit (PACU), the platform provides real-time visibility into procedural milestones, automating documentation directly into the EHR. This level of automation is designed to “reclaim” time for bedside nurses, who historically spend a significant portion of their shifts on administrative tasks rather than direct patient interaction.

Yeman Collier, Chief Information Officer at UChicago Medicine, emphasizes that the goal is to apply this technology in targeted ways that reinforce safety and enhance the patient experience. By integrating these tools directly into existing clinical workflows, the system aims to reduce the “administrative friction” that often leads to clinician burnout. The implementation ensures that as the health system expands its clinical footprint, its technology remains a support mechanism rather than a distraction.

Measurable Impacts on Safety and Throughput

The decision to scale Artisight across the enterprise is supported by significant performance metrics from existing deployments. Health systems utilizing Artisight’s Virtual Nursing capabilities have reported that bedside nurses save more than 25 minutes per patient admission or discharge. Perhaps more critically, the use of intelligent monitoring has been shown to reduce fall rates by as much as 78 percent, a metric that has a direct impact on both patient safety and hospital liability costs.

These outcomes reflect a shift toward “intelligent awareness” in the hospital environment. Dr. Andrew Gostine, CEO of Artisight, notes that the complexity of an academic medical center demands a cohesive platform rather than a collection of disparate tools. By deploying a unified sensor fabric, UChicago Medicine ensures that its future AI capabilities and new facilities are built on a consistent, scalable foundation that can adapt to the evolving needs of high-complexity patient care.

What You Should Know

• Beth Israel Lahey Health (BILH) is expanding its partnership with Heidi to provide ambient AI scribing capabilities to all of its more than 6,000 providers.
• An initial 6-month trial involving 1,000 providers resulted in 89% satisfaction regarding the quality of generated medical notes.
• The technology significantly impacts clinician well-being, with 82% of trial users reporting reduced cognitive load and 74% noting a reduction in time spent working outside of standard hours.
• Clinical quality was high, as 88% of physicians confirmed the AI accurately captured complex medical terminology during patient consultations.
• The rollout aims to address a national crisis, as nearly half of U.S. physicians currently report burnout, contributing to a turnover rate of 6-7%.

The pervasive issue of physician burnout has reached a critical threshold in the United States, with nearly half of all medical professionals reporting exhaustion due to administrative burdens. In New England, Beth Israel Lahey Health (BILH) is moving to combat this systemic stress by deploying ambient AI technology from Heidi across its entire network. Following a successful pilot program, the system is transitioning Heidi from a specialized tool to a foundational clinical partner for its 14 hospitals and 175 primary care practices.

The decision to scale the technology was driven by the significant impact ambient AI has on the daily caseload of clinicians. By automating the most time-consuming aspects of practice—such as clinical documentation and task management—the platform allows physicians to refocus on direct patient engagement. This shift is vital for BILH’s broader mission of improving both the workforce experience and patient outcomes through innovative, user-centric technology.

Clinician Adoption Through Customized Flexibility

A primary factor in the high adoption rates during the initial trial was the platform’s ability to adapt to individual physician workflows. Rather than forcing a standardized, one-size-fits-all documentation format, Heidi prioritizes the unique preferences of the end user. This “hyper-focus” on clinician-led championing ensures that the AI feels like a natural extension of the exam room rather than a top-down administrative mandate.

During the evaluation period, physicians noted that the technology allowed them to be more present during visits. Survey data revealed that 90% of users felt they could maintain more consistent eye contact and rapport with patients because they were no longer required to take copious manual notes. One BILH cardiologist described the information generated from the AI transcripts as more succinct and accurate than notes they would have dictated themselves, marking a significant milestone in clinical documentation quality.

Measurable Relief in a Constrained Environment

The benefits of the rollout extend beyond the exam room into the personal lives of the medical staff. Documentation often bleeds into a physician’s “pajama time”—hours spent finishing charts after the workday has ended. Heidi’s pilot showed that 74% of providers saw a decrease in these after-hours tasks, a metric that directly correlates with a reduction in burnout. Furthermore, 82% of surveyed users reported a lighter cognitive load, indicating that the AI effectively manages the “in-between” administrative rules that typically distract from clinical care.

As Beth Israel Lahey Health completes this national-scale implementation, it sets a new benchmark for how integrated delivery networks can leverage ambient AI to protect their workforce. By obsessing over the end-user experience and focusing on genuine clinical adoption, the partnership demonstrates that AI can deliver immediate relief to healthcare systems under strain. Heidi currently supports more than 2 million consults weekly across the globe, and this expansion solidifies its role as a leader in the evolving landscape of medical scribing.

Why This Matters

The “Heidi Model” at BILH provides a blueprint for successful digital transformation. The 89% satisfaction rate is a rare achievement for any new EHR-integrated technology and proves that when tools are “clinician-championed,” adoption becomes organic. If this rollout can maintain its current trajectory of reducing turnover and cognitive load, it will serve as the primary case study for health systems looking to stabilize their workforce through 2026 and beyond.

What You Should Know

• The Investment: Koda Health secured a Series A strategic investment from UPMC Enterprises to aggressively scale its AI-enhanced Advance Care Planning (ACP) platform across complex patient populations.
• The Financial Toll: The American healthcare system currently spends an estimated $200 billion annually on care that patients would not have wanted had they been engaged in care planning earlier in their journey.
• The Technology Engine: The platform navigates patients through condition-specific conversations via guided education and video, directly pushing their documented preferences into existing clinical workflows.
• The Human-in-the-Loop: High-acuity patients are paired with dedicated advocates who possess clinical backgrounds in social work or palliative nursing to provide longitudinal, human support.
• The Hard ROI: In a third-party validated study, Koda Health’s platform drove a 79% reduction in terminal hospitalizations, a 38% reduction in intensive care unit utilization, and a 19% drop in total cost of care for patients in their last year of life.

The Infrastructure of Serious Illness

The American healthcare system is currently burdened by a massive operational failure at the end of life. Every single year, roughly $200 billion is spent delivering medical interventions to patients who fundamentally would not have wanted those specific treatments if they had been properly consulted earlier in their disease progression. While proactive advance care planning is definitively proven to close this massive gap, successfully delivering and facilitating those sensitive conversations across large populations has historically been incredibly difficult for health systems to scale.

To permanently fix this systemic bottleneck, Koda Health  announced the closing of a Series A strategic investment led by UPMC Enterprises. The infusion of capital is designed to scale a new, digitally guided approach to care planning that explicitly targets complex patient populations. According to the investment team at UPMC Enterprises, this digitally guided, values-based planning architecture represents an underbuilt, yet absolutely critical, layer of modern serious illness infrastructure.

Bridging Algorithms and Clinical Empathy

Historically, technology-only approaches to serious illness planning have failed because they lack the empathy and nuance required for end-of-life discussions. Koda Health circumvents this by utilizing a sophisticated hybrid model. The platform leverages artificial intelligence to navigate patients through condition-specific educational videos, helping them formally document their core values, designated medical decision-makers, and explicit treatment preferences. Crucially, the resulting data does not sit in an isolated portal; the patient’s goals flow straight into the provider’s clinical workflows to ensure care teams can view them at the moments that matter most.

However, for the most complex, high-acuity cases, the technology steps back to let human expertise take the lead. These patients are matched with dedicated Koda Member Advocates who possess deep clinical experience in social work or palliative nursing. These specialists offer continuous, longitudinal support, ensuring that legal surrogates are fully aligned and that the patient’s documented plans accurately reflect the care they truly desire during a serious illness. Kathryn Heffernan, senior director at UPMC Enterprises, noted that investing in this type of infrastructure is essential for improving care delivery for the most vulnerable patients, highlighting Koda’s unique ability to blend hard clinical evidence with genuine compassion.

Monetizing Compassionate Care

Koda Health is not just selling a better patient experience; they are fundamentally rewiring the economics of serious illness. A third-party validated study tracking patients in their final year of life revealed that Koda’s intervention drove a staggering 79% drop in terminal hospitalizations. Furthermore, the platform reduced intensive care unit utilization by 38% and slashed the total cost of care by 19%.

Dr. Desh Mohan, Chief Medical Officer and Co-Founder of Koda Health, described the UPMC investment as a critical signal to the wider healthcare market. He emphasized that this financial backing proves health systems are finally ready to invest in proactive, highly scaled infrastructure that provides the necessary human support for these difficult conversations. Successfully demonstrating that compassionate care alignment yields massive systemic savings, Koda Health is establishing the potential blueprint for how advanced illness will be managed.

What You Should Know

• Sage has launched Tasking, a solution that unifies planned care from EHRs with unplanned care alerts into a single, real-time mobile workflow.
• The solution initially launches through a bi-directional integration with ALIS, ensuring care plans and frontline assistance are constantly in sync across both platforms.
• The platform addresses caregiver burnout by enabling point-of-care documentation, eliminating the need for staff to record care activities after their shifts end.
• Operational benefits include Level of Care (LOC) recommendations and staffing insights fueled by a complete data picture of both planned and unplanned resident needs.
• This launch follows Sage’s $65M Series C funding led by Goldman Sachs Alternatives, aimed at shifting the industry toward predictive, AI-powered prevention.

The senior living and skilled nursing industries have historically struggled with a “fragmentation gap.” While formal care plans are meticulously maintained within an Electronic Health Record (EHR), the reality of daily frontline work—consisting of real-time alerts and spontaneous resident needs—often lives in a separate, disconnected system or remains entirely undocumented. Sage, an integrated care platform, has moved to bridge this divide with the launch of Tasking. This new solution represents a fundamental shift in clinical operations, moving away from siloed data entry and toward a single, unified workflow for the caregiver.

By integrating directly with ALIS, a leading senior living software provider, Sage is enabling a bi-directional flow of information. This means that a task planned in the EHR is immediately visible to the caregiver on the floor, and any unplanned care delivered in response to an alert is instantly documented back into the resident’s record. This level of connectivity is designed to reduce the cognitive load on staff who previously had to jump between apps or paper notes, often resulting in incomplete records and clinical risks.

Reducing Burnout Through Point-of-Care Documentation

A primary driver for the development of Tasking is the pervasive issue of caregiver burnout. When documentation is treated as a separate administrative task to be completed at the end of a long shift, it becomes a significant burden. Ellen Johnston, Co-founder and Chief Product Officer of Sage, emphasizes that the goal is to make it as easy as possible for caregivers to document care “in the moment.” By bringing documentation into the natural flow of the workday, Sage aims to give frontline teams their time back, allowing them to focus on the human element of resident care rather than late-night administrative hurdles.

The platform’s high engagement rate—currently at 90%—suggests that care teams are already deeply reliant on Sage for their daily tasks. The addition of Tasking builds on this existing trust by centralizing all daily workflows into one intuitive app. For caregivers, this means a more predictable and manageable caseload; for residents, it means more consistent attention from a staff that is less preoccupied with impending paperwork.

Enhanced Visibility and Financial Performance for Operators

Beyond the frontline experience, Tasking provides a new layer of “operational intelligence” for community leadership. By capturing a complete picture of every care interaction—both scheduled and unscheduled—the platform can provide data-driven recommendations for staffing and Level of Care (LOC) adjustments. This visibility is critical for ensuring that communities are properly compensated for the actual care they provide and that staffing levels are optimized to meet real-time demand.

This announcement comes as Sage continues to demonstrate significant impact on the industry’s bottom line and safety standards. Sage-powered communities have already identified a $275 increase in Net Operating Income (NOI) per resident per month and a 50% reduction in falls compared to industry averages. With the recent $65M Series C investment led by Goldman Sachs Alternatives, Sage is positioned to further evolve its predictive AI capabilities, moving the sector from a reactive model of care to one defined by proactive prevention and dignity.

Why This Matters

The most valuable data is no longer just what you planned to do, but what your staff actually did. The partnership with ALIS create a bi-directional loop enables Sage to potentially solve the “data leakage” problem where millions of minutes of care go unrecorded each year.

With the advancements in traumatic wound care, the question is no longer whether we can close the wound — it’s how well we can restore what was lost.

Key Takeaways:

• Wound closure has long been the default measure of success in acute wound care; however, for patients, it is rarely the milestone that matters.
• Regenerative technologies, including autologous cell systems and dermal scaffolds, now enable higher-quality, more functional outcomes.
• Published evidence links these approaches to shorter hospital stays and meaningful per-patient cost reductions
• Health systems that follow the patient beyond discharge are uncovering substantial human and financial value that episode-based metrics miss.

Closure is a milestone, not an outcome.

There is a moment when treating a traumatic wound where surgeons feel their objective is complete: the wound is closed, the graft is intact, and the dressing is clean. For decades, closure has been considered the primary measure of success, shaping how we train surgeons, design care pathways, evaluate technologies, and report results. Nearly all of the metrics we track, the benchmarks we set, and the reimbursement structures we’ve built are anchored to this point.

Meanwhile, patients go home with grafted skin that pulls tight across their shoulder when they reach for a shelf. They avoid sleeveless shorts. They decline handshakes. They leave jobs that require physical labor. They carry the wound long after the chart says it’s closed.

We can, and should, do better for our patients, and technology is available now to demand more.

Skin Does More Than Blanket the Body

Skin is not decorative. It regulates body temperature, guards against infection, enables sensation, and provides the pliable architecture that enables movement. When trauma or burns occur, replacing the injured skin should be considered the bare minimum — not the goal.

Split-thickness skin grafting, the dominant technique for decades, is good at coverage but less effective for restoration. Grafts frequently differ in color and texture from native skin. They can stiffen and contract, especially over joints, creating a permanent mechanical disadvantage in the very body part the patient needs most. The donor harvest site opens a second wound that can be extremely painful, cause secondary infection, and scar visibly.

We have accepted these trade-offs because, for a long time, coverage was enough. It no longer is. It should now be the bare minimum.

Aligning Measurement with Technological Advances

Regenerative medicine has quietly transformed what is possible in reconstructive surgery. Point-of-care autologous cell systems can now take a skin sample the size of a postage stamp, process the patient’s own cells, and deliver them directly to a wound, supporting tissue regeneration that more closely mirrors native skin in pigmentation, pliability, and quality. It’s been found that in patients with deep partial-thickness burns, treatment with spray-on skin cell technology alone significantly reduced donor skin requirements by 97.5% compared to 2:1 meshed autografting. Smaller donor sites mean less pain and faster recovery. Better tissue quality means less contracture and better long-term mobility. Faster closure means less risk of infection. Combined, the patient leaves the hospital sooner to recover at home.

Dermal scaffold technologies are rebuilding the foundation beneath grafts, accelerating vascularization, and creating the biological conditions for durable, resilient tissue. These are not experimental curiosities but available tools that surgeons are already putting to use.

However, adoption remains uneven, largely because incentive structures don’t reward the outcomes these technologies improve. If a health system’s wound care program is evaluated on closure rates and length of stay, there is no data signal for “patient returned to full shoulder mobility” or “no revision surgery required at 18 months.” The benefit is real. It just isn’t measured.

The Cost Argument Is Stronger Than You Think

Advanced therapies do cost more upfront. Unfortunately, this is also where the analysis often stops, and where it shouldn’t.

A patient who avoids scar contracture does not require revision surgery. A patient with better donor-site healing is discharged sooner and requires less pain management. A trauma survivor who regains full function returns to work instead of entering a disability pathway. Studies have found that spray-on skin technology can reduce hospital length of stay by an average of 3.3 days, resulting in cost savings of nearly $37,000 per patient with burns of up to 50% TBSA. Economic modeling suggests hospital length of stay alone accounts for up to 70% of those cost reductions. When you follow the downstream economics rather than stopping at the initial procedure cost, the math adds up.

Health systems that have built the data infrastructure to track functional outcomes, readmissions, and long-term resource utilization are beginning to see this. Those still measuring wound care success at the point of closure are measuring the episode, not the recovery. The difference, in both human and financial terms, is significant.

What We Owe Patients and Ourselves

For a trauma survivor, feeling comfortable in their skin is not a luxury outcome. It is the point. The ability to move without restriction, to feel comfortable in their appearance, to return to work and relationships, and just plain old ordinary life is what recovery actually means to the person living it.

Healthcare leaders have both the opportunity and the obligation to build systems that pursue that standard. That means updating outcome frameworks to capture function, aesthetics, and quality of life. It means evaluating wound care technologies against the full arc of patient recovery, not just the acute episode. And it means being willing to challenge the comfortable assumption that closure is enough.

The tools to do better exist, and the evidence is there. The only thing still lagging is the willingness to redefine what success looks like and to hold our systems accountable for achieving it.

Closing a wound is where surgery ends. Restoring a life is where care begins.

About Saeed A. Chowdhry, MD 

Saeed A. Chowdhry, MD, has a busy clinical practice in the Chicago area and also serves as Associate Professor of Plastic Surgery at the Rosalind Franklin University of Medicine and Science, also known as The Chicago Medical School. Dr. Chowdhry is the Chairman and Chief of Plastic Surgery at Christ Hospital in the Chicago area. With close to 800 beds, it is one of the busiest Level I trauma centers and tertiary care referral centers in the Midwest. 

He was educated at Rush University College of Medicine and subsequently completed his General Surgery training at the University of Illinois at Mt. Sinai and Plastic Surgery fellowship training at the University of Louisville. While in training and in practice, he has won several research and teaching awards. He has authored peer-reviewed journal articles and book chapters that have been reviewed and cited over a thousand times in the surgical literature. Dr. Chowdhry has also served as a reviewer for several journals as well as the Cochrane Review and has been recognized for his expertise in reconstructive and cosmetic surgery.

What You Should Know

• Covera Health and Medmo have officially merged into a single organization, creating a unified platform that manages diagnostic imaging for nearly 6 million Americans.
• The combined entity is backed by additional capital from Insight Partners and serves major clients, including Walmart, Blue Cross Blue Shield of Michigan, and three of the five largest national health plans.
• Covera’s AI-driven platform focus on diagnostic accuracy has produced up to 12 percent lower downstream healthcare costs by routing patients to high-performing Centers of Excellence.
• Medmo’s care coordination technology has facilitated over 1 million patient journeys, delivering a 35 percent reduction in radiology spend and 30 percent higher study completion rates.
• The new infrastructure “closes the loop” in radiology, managing the entire lifecycle from the initial referral and scheduling to the delivery of clinically significant findings.

In the modern healthcare journey, radiology is often the point where critical clinical decisions are made—and where care frequently goes off the rails. A study that is never completed, performed at a sub-par facility, or interpreted with insufficient precision can contaminate every subsequent treatment decision. Covera Health and Medmo have announced their combination to solve this foundational crisis, merging Covera’s expertise in diagnostic quality with Medmo’s high-touch care coordination infrastructure.

Historically, health plans and employers have struggled with the “invisible variation” in imaging quality. The same MRI, ordered for the same clinical reason, can yield vastly different results depending on the facility and the radiologist. By joining forces, Covera and Medmo are creating the first platform that ensures a patient not only reaches the right imaging center but that the resulting report is accurate and actionable for the entire care team.

Solving the “Visibility Gap” from Referral to Results

One of the most persistent hurdles in diagnostic imaging is that providers often lose visibility the moment a patient walks out of the office with a paper order. Medmo was built specifically to close this gap by managing the patient journey through scheduling, prior authorization, and engagement. Operating in all 50 states, the Medmo platform has already demonstrated a 30 percent increase in study completion rates, ensuring that the “missing foundation” of a diagnosis is actually captured.

By integrating Medmo’s coordination engine with Covera’s AI-powered quality oversight, the combined organization now brings clinical intelligence to every step of the imaging process. Covera’s platform measures accuracy across more than 1,100 sites, routing members to “Centers of Excellence” that have been actuarially validated to improve outcomes. This ensure that when a study is finally performed, it serves as a reliable basis for authorized procedures and interventions.

A New Infrastructure for Value-Based Care

For the thousands of value-based primary care physicians now connected to the combined platform, this merger provides a strategic “system of action.” The infrastructure doesn’t just record data; it surfaces clinically significant findings and routes them back to the referring physician in real-time. This level of integration is essential for managing downstream utilization and preventing the unnecessary procedures that often stem from flawed initial reports.

Jeff Horing, Co-Founder and Managing Director at Insight Partners, noted that diagnostic quality is the “missing foundation” of the value-based care movement. The additional capital provided by Insight Partners is intended to accelerate the expansion of this new model, moving it from an incremental improvement to a foundational piece of national healthcare infrastructure. As the organization scales, it aims to continue driving down radiology spend while simultaneously increasing the precision of the U.S. healthcare system.

Why This Matters

For healthcare executives, this represents a move toward “Integrated Diagnostic Management.” As employers and payers face mounting pressure to control costs, the 12 percent reduction in downstream expenses offered by Covera’s platform becomes a powerful lever. This combined entity isn’t just a new vendor; it’s a quality-control layer for the most critical diagnostic tool in the medical arsenal.

What You Should Know

• Availity has launched the 2026 Abrasion Index, a dual-sided research report quantifying administrative friction between U.S. health plans and healthcare providers.
• Denials emerged as the most severe abrasion point, with the report finding that ~70% of denials are ultimately overturned and paid, creating significant administrative “churn”.
• Prior authorization remains a critical burden, with physicians averaging 13 hours per week on the process and 89% reporting it contributes to burnout.
• The research highlights a timing vs. accuracy gap: many administrative failures occur not because of incorrect data, but because correct information arrives too late to prevent downstream damage.
• Payer abrasion is often equal to or higher than provider abrasion, driven by legacy system technical debt and employer-specific plan variation.

The infrastructure of American healthcare administration is currently defined by a “compounding systems problem” where upstream signals fail to hold downstream. Availity, the nation’s largest health information network, has released its inaugural Availity Abrasion Index to provide a measurable baseline for this operational wear. The report argues that what the industry often views as episodic friction is actually systemic abrasion—cumulative operational wear that erodes trust, increases costs, and limits the ability of health systems and plans to scale effectively.

The findings suggest that the most costly failures occur in the “in-between”: the space where information must be interpreted and acted upon across organizational boundaries. This is not merely a story of provider burden; payers report substantial internal overload driven by the complexity of managing fragmented workflows at scale. According to Availity CEO Russ Thomas, the industry is caught in an “endless cycle of rework” that can only be broken by addressing these friction points through shared infrastructure and earlier visibility.

The Structural Reality of Denials and Prior Authorization

Denials represent the most severe source of abrasion identified in the report. Rather than acting as isolated error corrections, denials have become a persistent operating layer of cost control and dispute. The statistic that approximately 70% of denials are eventually overturned highlights a massive coordination failure: billions of dollars are potentially wasted arguing over claims that should have been paid at the initial submission. This “avoidable churn” is often driven by technicalities or timing issues, such as a claim being processed before a benefit update is fully synced.

Similarly, prior authorization continues to be a primary driver of care delays and clinician burnout. While 90% of payers view the process as necessary for cost control, only 47% agree that their own staff have adequate tools to make timely, accurate decisions. This mismatch between intent and execution leads to a reality where 82% of providers agree that initial denials and slow response times directly delay patient care. The report characterizes this not as a lack of goodwill, but as a failure of standardized, API-enabled workflows to keep pace with clinical needs.

Bridging the “Last-Mile” Clinical Data Gap

A significant portion of the administrative burden is tied to clinical data exchange, which remains stubbornly manual even in an EHR-driven world. This “last-mile problem” means that while claims are submitted electronically, the supporting documentation often moves through faxes, PDFs, and mail. This fragmentation leads to matching and routing failures where records arrive but cannot be mapped back to the correct claim, often resulting in “phantom” denials for missing information that the payer may already possess.

The report highlights that 70% of payers find medical records difficult to analyze because they are not in standard formats. This manual sift increases internal costs for plans and forces providers into “proof-seeking” behavior, such as sending records via certified mail to ensure receipt. To move toward what Availity calls “Harmonizing Healthcare,” the industry must shift from reactive, denial-based record acquisition to proactive, data-first workflows where attachments are treated as an integrated part of the claim lifecycle.

Why This Matters

High electronic adoption has masked a collapse in trust because digital transactions are still being invalidated by retroactive data changes. The competitive advantage in 2026 will belong to those who move “left” in the revenue cycle—using neutral, shared infrastructure to validate eligibility and authorization at the point of care, rather than fighting it out in the appeals department six months later.

Hospital leaders are navigating one of the most transformative periods in modern healthcare as organizations invest heavily in artificial intelligence, predictive analytics, and digital infrastructure. Yet one of the deadliest and most expensive forms of preventable harm inside hospitals receives far less strategic attention than it deserves: hospital-acquired pressure injuries.

Pressure injuries contribute to an estimated 60,000 deaths annually in the United States, according to the Agency for Healthcare Research and Quality. That exceeds annual deaths from traffic accidents or influenza in many reporting periods. Nearly everyone will spend time in a hospital at some point in life, yet this risk remains largely invisible in public discourse and, too often, in executive strategy.

Through years of working alongside health systems and clinical teams, I have come to believe that pressure injury prevention represents a fundamental operational gap in modern healthcare delivery.

A Known Problem That Persists

Pressure injuries are not new. Clinical guidelines are well established, and prevention protocols have existed for decades. Hospitals understand risk factors, assessment tools, and recommended interventions.

Still, approximately 2.5 million patients develop pressure injuries in U.S. acute care settings each year. Critically ill patients face even higher exposure, with research showing that up to one in four ICU patients may develop a pressure injury during hospitalization.

The financial consequences are significant. Pressure injuries cost the healthcare system an estimated $26.8 billion annually. Individual cases can add between $20,900 and $151,700 in treatment costs. The National Pressure Injury Advisory Panel reports average legal settlements exceeding $200,000, contributing to roughly 17,000 lawsuits each year.

When outcomes remain unchanged despite widespread awareness, the issue is no longer clinical knowledge. It is operational execution.

The Gap Between Insight and Action

Healthcare has become exceptionally good at identifying risk. Electronic health records calculate scores automatically. Predictive analytics highlight vulnerable patients. Dashboards track quality indicators in real time. What these systems do not guarantee is that preventive care happens consistently at the bedside.

Repositioning and mobility, the core defenses against pressure injuries, depend on coordinated physical action delivered repeatedly throughout a patient’s stay. In many hospitals, execution relies almost entirely on nurses and frontline caregivers already managing heavy workloads and rising patient acuity.

Even highly skilled teams struggle to maintain perfect adherence when workflows compete for limited time and staffing. Technology can signal risk, but alerts alone do not move patients.

This creates a disconnect between digital intelligence and physical care delivery. Healthcare is measuring risk with precision while relying on fragile systems to address it.

A Workforce Challenge as Much as a Patient Safety Issue

Pressure injuries are often framed as patient outcomes, though they are equally tied to workforce sustainability.

Safe repositioning and mobility require physical effort. According to the Occupational Safety and Health Administration, musculoskeletal injuries linked to patient handling remain among the most common workplace injuries in healthcare. When caregivers are injured or fatigued, staffing shortages deepen and preventive care becomes harder to sustain.

In my conversations with nurse leaders, a consistent theme emerges. Care teams know what excellent prevention looks like. The difficulty lies in delivering it reliably within operational constraints.

Burnout grows when clinicians feel accountable for outcomes that depend on systems beyond their control.

Improving prevention therefore supports two priorities health systems are trying to solve simultaneously: protecting patients and stabilizing the workforce.

Why Prevention Requires Operational Ownership

Healthcare has successfully reduced harm in other areas by redesigning systems rather than relying solely on individual vigilance. Infection prevention improved through standardized workflows. Surgical safety advanced when structured processes reinforced consistency across teams.

Pressure injury prevention has not yet undergone the same operational evolution.

Hospital leadership teams should reconsider how prevention fits into enterprise strategy.

• First, mobility must be treated as a core clinical workflow supported by dedicated resources and accountability, not an additional task added to already full workloads.
• Second, measurement should focus on reliability of care delivery rather than documentation alone. Charting compliance does not always reflect whether preventive interventions occurred consistently.
• Third, technology investments should connect analytics directly to operational response. Predictive insights generate value only when systems exist to act on them dependably.
• Finally, leaders should evaluate prevention through a total-value perspective. Pressure injuries influence length of stay, reimbursement exposure, litigation risk, workforce injuries, and patient trust at the same time.

The Next Phase of Healthcare Transformation

Healthcare transformation is often discussed in terms of innovation and digital capability. Those advances are essential, but transformation also requires strengthening the reliability of fundamental care.

Patients enter hospitals assuming they will be protected from preventable harm during moments when they are least able to protect themselves. Pressure injuries challenge that expectation because they develop gradually, often unnoticed until damage becomes severe.

The industry does not lack awareness or clinical expertise. What it lacks is operational alignment that ensures prevention happens consistently for every patient.

If healthcare leaders want digital transformation to deliver its full promise, we must close the gap between what we know and what reliably occurs at the bedside. Pressure injury prevention offers a clear opportunity to do exactly that.

Until it becomes a strategic priority owned at the leadership level, one of the most lethal and costly complications in hospital care will remain a safety crisis hiding in plain sight.

About Eric Race, CEO of Atlas Mobility

Eric Race is the Founder and CEO of Atlas Mobility, a healthcare technology company headquartered in Miami, FL and San Francisco, CA. Atlas improves mobility, safety, and patient outcomes inside hospitals across the United States. Over the past decade, Eric has built Atlas from the ground up into a nationally deployed clinical operations company and FDA-registered medical device organization with approximately 400 employees nationwide. The company partners with leading health systems to reduce workplace injuries, standardize safe patient movement, and modernize frontline clinical operations. 

What You Should Know

• TytoCare has received FDA De Novo classification for its Tyto Insights for ENT Suite, creating a first-of-its-kind regulatory category for “ear, nose, and throat image analyzers”.
• The AI-powered tool automatically analyzes otoscopy video to detect eardrum bulging, a primary indicator of Acute Otitis Media and other common pediatric conditions.
• Designed for patients aged six months and older, the system uses a proprietary database of 1.6 million ear images to provide clinical decision support to providers.
• The technology aims to reduce unnecessary antibiotic usage and treatment delays by providing more accurate assessments than traditional telehealth solutions.
• TytoCare is also launching Smart Checkup capabilities, allowing patients to receive direct insights about their own lung and ear exams through the Smart Clinic Companion.

Pediatric ear infections account for approximately 20 million doctor visits annually in the United States, yet they remain one of the most difficult conditions to assess accurately via standard telehealth. TytoCare, a leader in home-based primary care technology, has achieved a landmark regulatory milestone to address this gap. By securing FDA De Novo classification for its Tyto Insights for ENT Suite, the company has not only launched a new product but has established an entirely new regulatory category for AI-driven ENT image analysis.

The platform adds a sophisticated intelligence layer to TytoCare’s existing digital otoscope. By analyzing video recordings of the eardrum in real-time, the AI can identify bulging with a degree of consistency that was previously difficult to achieve in a remote setting. This breakthrough is particularly significant as the U.S. continues to face a mounting shortage of primary care physicians, putting increased pressure on home-based diagnostic tools to be both accurate and actionable.

Bridging the Diagnostic Gap in Pediatric Primary Care

The development of the ENT Suite was made possible by TytoCare’s massive proprietary database, which contains over 1.6 million ear images and recordings. This multimodal data allows the AI to serve as a reliable clinical support tool, helping providers differentiate between conditions that require immediate intervention and those that do not. The ability to accurately detect eardrum bulging is a critical lever in the fight against antibiotic over-prescription—a major concern in pediatric medicine.

Beyond support for clinicians, the new ENT Suite is designed to inform the patient or caregiver directly. This transparency is intended to foster a deeper understanding of the condition and more informed decision-making within the home. By providing results that are easy to interpret, TytoCare is empowering parents to engage more effectively with their clinicians, turning a routine home exam into a collaborative healthcare journey.

A Foundation for Multi-Modal AI Diagnostics at Scale

The FDA De Novo classification is more than just a single product milestone; it represents a fundamental shift in how primary care can be delivered. As Elad Lachmanovich, Chief Technology and Product Officer of TytoCare, noted, this classification establishes the foundation for a new generation of AI-driven diagnostics. The vision is for an AI layer that can interpret clinical-grade data across multiple exam types—including heart, lungs, throat, and skin—and turn it into actionable insight at scale.

In parallel with this regulatory win, TytoCare is enhancing its Smart Clinic Companion with “Smart Checkup” capabilities. This update leverages both the Lung Suite and the new ENT Suite to give patients a more comprehensive view of their health status during remote examinations. As these tools continue to learn from millions of real-world interactions, the goal is to create a seamless triage and diagnostic ecosystem that brings high-quality, clinical-grade care into the living room without requiring an in-person visit.

Why This Matters

TytoCare is paving the way for a future where the “home clinic” is the first line of defense, effectively alleviating the burden on a shrinking physician workforce. This isn’t just about ear infections; it’s about the clinical validation of the home.

What You Should Know

• The FDA has cleared Tandem’s Control-IQ+ technology for use in pregnancies complicated by type 1 diabetes, making it the first and only commercially available AID system with this indication in the U.S.
• The expanded label applies to both of Tandem’s delivery systems: the t:slim X2 and the Tandem Mobi.
• In the CIRCUIT trial, participants using Control-IQ+ spent 12.6% more time in the pregnancy-specific glucose target range (63-140 mg/dL) compared to those on standard therapy.
• Clinical improvements were observed within the first week of initiation and persisted through the end of the pregnancy. Maternal and neonatal outcomes in the study favored the group using Control-IQ technology over traditional multiple daily injections or standard pump therapy.

Managing type 1 diabetes during pregnancy is a high-stakes balancing act where glycemic goals are significantly tighter than for the general population. Historically, expectant mothers have had to rely on multiple daily injections or standard insulin pumps without the benefit of automated, pregnancy-specific adjustments. Tandem Diabetes Care has fundamentally altered this landscape with the FDA clearance of Control-IQ+ technology. This milestone establishes the t:slim X2 and Tandem Mobi as the first and only insulin delivery systems in the United States authorized to support patients through the complexities of gestation.

The clearance addresses a critical gap in the diabetes technology market. Because glucose targets are more aggressive during pregnancy, the need for automated adjustments to basal insulin delivery is paramount to avoid both maternal and neonatal complications. Dr. Jordan Pinsker, Chief Medical Officer at Tandem, emphasized that the technology is specifically designed to help patients achieve the higher “time in range” required for successful pregnancy outcomes, providing a level of precision that manual management often struggles to maintain.

Proven Efficacy: The CIRCUIT Trial Results

The FDA’s decision was heavily informed by data from the CIRCUIT trial, a multi-center study published in the Journal of the American Medical Association (JAMA). The results showed that users of the Control-IQ technology achieved approximately three additional hours per day within the pregnancy-specific glucose target range of 63-140 mg/dL. These gains were not limited to a specific demographic; improvements were noted across all study sites and regardless of the patient’s baseline HbA1c levels or previous insulin delivery methods.

According to Dr. Lois Donovan, the study’s principal investigator, the glycemic benefits were almost immediate. Improvements were recorded within the first seven days of initiating the system and remained stable until the conclusion of the pregnancy. This sustained performance is a significant indicator of the system’s reliability in handling the physiological shifts—such as increasing insulin resistance—that typically occur during the second and third trimesters.

Expanding Clinical Infrastructure and Provider Education

With this new indication, Tandem is launching an extensive educational campaign to prepare healthcare providers for the integration of AID systems into prenatal care. The initiative will kick off in June 2026 at the American Diabetes Association Scientific Sessions in New Orleans, where the company will host a product theater to detail the CIRCUIT study findings. This reflects a broader commitment to ensuring that maternal-fetal medicine specialists and endocrinologists have the training necessary to deploy these systems effectively.The pregnancy clearance is the latest in a series of research-backed expansions for the Control-IQ platform. Since 2019, major studies published in the New England Journal of Medicine have consistently demonstrated the platform’s ability to improve sleep and time in range across diverse populations. By extending these benefits to the pregnancy category, Tandem is not just expanding its product label; it is providing a vital clinical lifeline to a population that has long been underserved by automated healthcare technology.

What You Should Know

• St. Luke’s University Health Network (SLUHN) is collaborating with Auxira Health to integrate virtually-embedded teams into its Heart & Vascular network.
• The model provides each cardiologist with a virtual support team of nurse practitioners, medical assistants, and registered nurses to manage follow-ups and care coordination.
• The initiative launches with 24 cardiologists, with established plans to expand across multiple St. Luke’s locations in Pennsylvania and New Jersey.
• The partnership aims to reduce after-hours EHR time and administrative burdens, allowing clinicians to focus on high-value patient interactions.

Cardiovascular disease remains the leading cause of death in the United States, impacting more than one in three adults. In the face of these rising clinical demands, St. Luke’s University Health Network—a non-profit system recently ranked as the top health system in the country for quality and safety—is rethinking the traditional cardiology workflow. By partnering with Auxira Health, St. Luke’s is introducing a physician-led, team-supported model designed to increase patient access without compromising the personal doctor-patient relationship.

The collaboration centers on a virtually embedded care team that handles the “digital friction” of modern medicine. These teams, comprised of advanced practice providers and medical assistants, take ownership of routine follow-ups, documentation, and care coordination. This structural shift is intended to protect the time cardiologists spend diagnosing and treating complex cases, ensuring that patients receive timely appointments in a landscape where heart disease mortality rates remain a significant public health challenge in both Pennsylvania and New Jersey.

Seamless Integration into Existing Clinical Workflows

A critical component of the Auxira model is its ability to embed directly into St. Luke’s existing infrastructure. Rather than requiring physicians to learn new platforms, the virtual teams operate within the network’s current operational workflows and its Epic electronic medical record (EMR) system. This “invisible” integration is designed to streamline day-to-day tasks and reduce the significant amount of time clinicians typically spend on administrative work after hours.

By leveraging existing technology and staffing resources, the partnership allows St. Luke’s to scale its heart and vascular services across its 16 hospital campuses and 350+ outpatient sites. Dr. Ray Durkin, cardiology chair at St. Luke’s, noted that the collaboration strengthens the connection between patients and their doctors by surrounding them with a broader support system. This ensures that every patient receives the continuity of care they require while maintaining the high standards of a nationally recognized “Top 50 Heart Hospital”.

Prioritizing the Human Connection in a High-Tech Future

While the underlying technology is sophisticated, the primary goal of the collaboration is human-centered. Auxira’s model is built on the belief that the future of cardiology lies in strengthening—not replacing—the bond between patients and their physicians. By delegating administrative burdens to the virtual team, cardiologists can devote more individual attention to high-value patient moments. This approach is particularly valued by older patient populations who prioritize face-to-face time with their specialists.

The mission aligns with St. Luke’s legacy as a regional pioneer in cardiovascular medicine, dating back to the first open-heart surgery in the region in 1983. With a team-based care model, the network is working to ensure that its services remain sustainable for providers and accessible for the community. As heart disease projections suggest that half the adult population may be affected by 2035, this proactive shift toward an integrated, efficient care model represents a vital step in maintaining long-term community health.

What You Should Know

• No Barrier’s AI-powered medical interpretation platform was tested in an independent study at Mass General Brigham, published in the New England Journal of Medicine (NEJM) Catalyst.
• The research compared Remote Video Interpretation (RVI), No Barrier’s real-time AI, and a hybrid approach to assess patient preferences using a modified technology acceptance model (TAM).
• Findings indicate that RVI is preferred for emotionally sensitive or high-stakes surgical conversations, while No Barrier’s AI is valued for its instant speed and privacy.
• The study involved 23 adult Spanish-speaking surgical patients at Brigham and Women’s Hospital to explore perceived usefulness, ease of use, and cultural alignment.
• No Barrier provides HIPAA-compliant translation in over 40 languages, designed to treat language access as a critical clinical process rather than a supplemental service.

For patients with Non-English Language Preference (NELP), the surgical journey is often fraught with communication barriers that can impact both emotional well-being and clinical outcomes. A new study conducted at Mass General Brigham and published in NEJM Catalyst has shed light on the evolving role of artificial intelligence in bridging these gaps. By integrating No Barrier’s real-time AI translation platform into the clinical environment, researchers explored how technology can move beyond traditional models to provide more flexible, patient-centric care.

The study utilized a modified technology acceptance model (TAM) to go beyond technical functionality. Researchers evaluated patient perspectives based on emotional resonance, trust, and cultural alignment. This approach recognizes that in a surgical setting, “understanding” the words is only half the battle; the patient must also feel a sense of security and human connection. The results emphasize that a one-size-fits-all approach to medical interpretation is no longer sufficient for modern healthcare organizations.

The Case for a Hybrid Interpretation Infrastructure

One of the most significant findings from the Mass General Brigham study is the patient demand for choice. While Remote Video Interpretation (RVI) remains a vital tool for navigating complex emotional nuances in high-stakes discussions, No Barrier’s AI interpretation was highly valued for its immediacy and the privacy it affords patients during routine communication. Patients participating in the study explicitly expressed that a “combination would be ideal,” suggesting that the future of language access is a hybrid infrastructure.

No Barrier CEO Eyal Heldenberg noted that the report validates an “AI-first” approach that is consistently reinforced by human expertise. By providing an instant interface for real-time medical communication, the platform eliminates the delays often associated with scheduling or connecting to live interpreters. This speed is critical in surgical workflows where timely information exchange can directly influence the pace of care and the patient’s level of anxiety.

Designing Care Delivery Around Flexibility and Trust

The study focused on a cohort of Spanish-speaking adult patients from the Department of Surgery at Brigham and Women’s Hospital. By using purposive sampling to explore their perceptions, the authors were able to develop an implementation framework for AI-based interpretation that prioritizes the patient experience. This framework suggests that language access should be embedded into the core of care processes, utilizing HIPAA-compliant tools to ensure data integrity and patient confidentiality across more than 40 languages.

Dr. Ilan Shapiro, Medical Advisor at No Barrier, emphasized that engagement improves when patients are met where they are. A hybrid model acknowledges the varying realities of patient needs—offering a human voice for the most difficult moments while providing a private, instant AI assistant for daily clinical interactions. This flexibility is not just an operational perk; it is a fundamental requirement for building trust with underserved populations and ensuring that every patient feels heard throughout their surgical journey.

Why This Matters

Organizations that offer a spectrum of choices—from RVI to AI-driven tools like No Barrier—will see higher patient satisfaction and more efficient clinical workflows. In an increasingly diverse U.S. patient population, treating language access as a critical care component rather than a checkbox item will be a defining differentiator for elite health systems.

What You Should Know

• Accenture Ventures has made a strategic investment in Iridius, an enterprise AI infrastructure company specializing in compliant-by-design solutions for highly regulated industries.
• The partnership will build end-to-end compliance workflows across the life sciences value chain, covering regulatory submissions, pharmacovigilance, and clinical operations.
• Iridius technology uses a knowledge engine to translate complex global regulatory standards into machine-readable logic, embedding compliance directly into automated enterprise workflows.
• The collaboration aims to accelerate clinical and regulatory timelines while significantly reducing the manual burden of maintaining ongoing audit readiness.

The journey from drug discovery to patient delivery is governed by a complex web of global regulations that often act as a brake on digital transformation. While AI offers the potential to radically accelerate this timeline, life sciences organizations have historically been hesitant to move beyond small-scale pilots due to concerns over data integrity and patient safety. Accenture has moved to eliminate this “innovation hesitation” by investing in and partnering with Iridius, a pioneer in compliant-by-design AI infrastructure.

The collaboration represents a fundamental shift in how compliance is handled in the pharmaceutical sector. Rather than treating auditability as a post-hoc manual check, the Iridius platform embeds regulatory logic into the system architecture itself. This ensures that every AI-driven decision is traceable and every workflow is continuously monitored for compliance during execution, turning a traditional risk management burden into a core operational capability.

Translating Regulation into Machine-Readable Logic

At the core of the Iridius platform is a sophisticated knowledge engine designed to ingest thousands of pages of standard operating procedures (SOPs) and regulatory standards. By converting these documents into structured, machine-readable logic, Iridius allows life sciences firms to apply compliance as a foundational element of system design. This architecture ensures that as AI systems run, they are inherently incapable of operating outside the defined regulatory boundaries.

Ray Pressburger, global life sciences lead at Accenture, emphasizes that this investment is about enabling innovation at scale. By integrating Iridius’ intelligent solution factory with Accenture’s global delivery capacity, the partnership will help organizations orchestrate compliant workflows across the entire pharmaceutical value chain. This includes high-stakes areas such as pharmacovigilance and manufacturing operations, where transparency and data integrity are non-negotiable requirements for maintaining institutional trust.

Moving from Manual Audits to Continuous Readiness

One of the most significant pain points in the life sciences industry is the heavy reliance on manual compliance work, which often leads to delayed clinical timelines and increased operational costs. The Iridius-Accenture partnership addresses this by creating a “solution factory” for compliant AI. By automating the evidence generation process, the platform maintains a state of ongoing audit readiness, allowing organizations to focus resources on research and development rather than administrative oversight.

Mike Kropp, Co-Founder and CEO of Iridius, notes that the goal is to reimagine complex workflows so that compliance becomes a strategic advantage rather than a defensive hurdle. As global regulatory landscapes continue to evolve, the ability to rapidly update machine-readable logic ensures that enterprises can stay ahead of new requirements without needing to overhaul their entire digital infrastructure. This adaptability is critical for scaling AI in an environment where the rules of the game are constantly being rewritten.

Why This Matters

For the broader healthcare and tech ecosystem, this partnership highlights the rising value of the “Translation Layer”—the technology that turns human laws into machine instructions. If Iridius and Accenture can successfully compress clinical and regulatory timelines by even a fraction, the economic and patient impact will be measured in billions of dollars and millions of lives.